Brief: Dextech: Follow-up Results From OsteoDex Study Indicate Prolonged Survival

Dextech Medical AB

14/10/2019 13:45

Oct 14 (Reuters) - Dextech Medical AB  DEXTECH.TE :
    * PROMISING FOLLOW-UP RESULTS FROM DEXTECH'S PHASE IIB STUDY FOR OSTEODEX
    * RESULTS INDICATE PROLONGED SURVIVAL AFTER OSTEODEX TREATMENT
    * RESULTS AS OF OCTOBER 14 SHOW FOLLOWING: PATIENTS WITH STABLE DISEASE (UNCHANGED)
REGARDING
SKELETAL METASTASIS AT END OF TREATMENT, 58% ARE ALIVE
    * PATIENTS WHO DISCONTINUED TREATMENT OR COMPLETED TREATMENT WITH PROGRESSIVE DISEASE
(PROGRESSIVE
DISEASE DEVELOPMENT) 48% ARE ALIVE
    * PATIENTS WHO COMPLETED TREATMENT AND HAD OBJECTIVE REGRESSION OF SKELETAL METASTASIS
(REDUCTION
OF EXISTING SKELETAL METASTASES), 86% ARE ALIVE
    * RESULTS OBTAINED SHOW THAT OSTEODEX ACTS AS A BRAKE MEDICINE FOR METASTATIC
CASTRATION-RESISTANT
PROSTATE CANCER

Source text for Eikon:  ID:nWkrQ32Dr 
Further company coverage:  DEXTECH.TE 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))